Starton Holdings, Inc. (STA) — SEC Filings
Starton Holdings, Inc. (STA) — 1 SEC filings. Latest: S-1 (Dec 11, 2025). Sentiment: mixed. Includes 1 S-1. Overall sentiment: mixed.
View Starton Holdings, Inc. on SEC EDGAR
Overview
Starton Holdings, Inc. (STA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-1 filed on Dec 11, 2025: Starton Holdings, Inc. (STA) is a clinical-stage biotechnology company focused on improving standard-of-care cancer therapies through proprietary continuous delivery technology systems. The company's lead program, STAR-LLD, is a continuous delivery system for lenalidomide, targeting multiple myeloma
Sentiment Summary
Across 1 filings, the sentiment breakdown is: 1 mixed. The dominant filing sentiment for Starton Holdings, Inc. is mixed.
Filing Type Overview
Starton Holdings, Inc. (STA) has filed 1 S-1 with the SEC between Dec 2025.
Recent SEC Filings (1)
| Date | Form | Description | Risk |
|---|---|---|---|
| Dec 11, 2025 | S-1 | Starton Holdings Eyes IPO to Fund Continuous Delivery Cancer Therapies | high |
Risk Profile
Risk Assessment: Of STA's 1 recent filings, 1 were flagged as high-risk, 0 as medium-risk, and 0 as low-risk. The overall risk profile suggests elevated risk that warrants close monitoring.
Key Executives
- Pedro Lichtinger Waisman
Industry Context
The clinical-stage biotechnology sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Starton operate in a competitive landscape focused on improving existing therapies through novel drug delivery systems. The oncology market, in particular, is a major focus for innovation, driven by unmet medical needs and the potential for substantial returns on successful drug development.
Top Tags
Biotechnology (1) · Oncology (1) · Drug Delivery (1) · S-1 Filing (1) · IPO (1) · Clinical Stage (1) · Lenalidomide (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Shares of Common Stock | 6,666,667 | Number of shares offered in the initial public offering |
| Initial Public Offering Price Range | $5.00 - $7.00 | Estimated price per share for the IPO |
| Underwriters' Over-Allotment Option Shares | 1,000,000 | Additional shares underwriters can purchase within 45 days |
| Potential Applications Evaluated | 80,000 | Number of drug applications evaluated by McKinsey & Company for continuous delivery |
| Timeline for Second Program Announcement | 12-18 months | Expected timeframe for disclosing Starton's next product candidate |
Frequently Asked Questions
What are the latest SEC filings for Starton Holdings, Inc. (STA)?
Starton Holdings, Inc. has 1 recent SEC filings from Dec 2025, including 1 S-1. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of STA filings?
Across 1 filings, the sentiment breakdown is: 1 mixed. The dominant sentiment is mixed.
Where can I find Starton Holdings, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Starton Holdings, Inc. (STA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Starton Holdings, Inc.?
Financial highlights for Starton Holdings, Inc. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for STA?
The investment thesis for STA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Starton Holdings, Inc.?
Key executives identified across Starton Holdings, Inc.'s filings include Pedro Lichtinger Waisman.
What are the main risk factors for Starton Holdings, Inc. stock?
Of STA's 1 assessed filings, 1 were flagged high-risk, 0 medium-risk, and 0 low-risk.
What are recent predictions and forward guidance from Starton Holdings, Inc.?
Forward guidance and predictions for Starton Holdings, Inc. are extracted from SEC filings as they are enriched.